Short answer
Travere Therapeutics, Inc. (TVTX) filed an 8-K current report with the SEC on September 21, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). CEO transition effective December 1, 2026, with Bradley Campbell replacing Eric Dube and joining the Board.
Travere Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- CEO transition effective December 1, 2026, with Bradley Campbell replacing Eric Dube and joining the Board
- Campbell brings Amicus CEO and commercialization experience following BioMarin’s April 2026 acquisition of Amicus
- New CEO compensation includes $1,000,000 salary, 85% bonus target, $500,000 expense payment, and approximately $20,250,000 equity awards
- Initial equity awards comprise approximately $8,250,000 stock options and $8,250,000 time-based RSUs, plus $3,750,000 performance-based RSUs
- Dube remains through February 15, 2027, with continued salary, equity vesting provisions, and consulting eligibility for up to 18 months
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Travere Therapeutics, Inc. 8-K filings
Get the next TVTX 8-K as it lands
Follow TVTX for push alerts, or ask the research agent what this filing means.